3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Squamous Cell
1
Interventions
Cisplatin
89
pembrolizumab
83
Magnetic Resonance Spectroscopy
47
Radiotherapy, Intensity-Modulated
41
Specimen Handling
37
Cetuximab
37
Carboplatin
37
Radiotherapy
36
Nivolumab
29
Paclitaxel
25
Platinum
23
Radiation
22
Docetaxel
22
Gemcitabine
21
Biopsy
21
1,2-diaminocyclohexaneplatinum II citrate
21
Surveys and Questionnaires
17
Fluorouracil
14
toripalimab
13
Standard of Care
13
Taxes
11
Cyclophosphamide
10
cemiplimab
9
atezolizumab
9
X-Rays
9
Surgical Procedures, Operative
9
Ipilimumab
9
Immunoglobulin G
9
Drug Therapy
9
Capecitabine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
ficlatuzumab
×
Head & Neck
×
90 days
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled